{"id":1303,"date":"2019-07-17T22:15:59","date_gmt":"2019-07-17T22:15:59","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1303"},"modified":"2026-02-24T00:36:45","modified_gmt":"2026-02-24T00:36:45","slug":"one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/","title":{"rendered":"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster)"},"content":{"rendered":"

Pathogenic variants in a number of genes, conferring high or moderate risks have been associated to hereditary breast cancer. Studying a highly selected cohort of 1,382 Greek breast cancer patients, 436 inherited pathogenic variants distributed in twenty-eight genes, have been identified. Beyond established associations, i.e. high breast cancer risk conferred by TP53<\/em> and PALB2<\/em> pathogenic variants, most importantly, novel associations involving RAD51C<\/em> and missense CHEK2<\/em> damaging variants to moderate risk of breast cancer, emerged. Since gene panel testing is nowadays part of everyday clinical practice, these data can provide meaningful clinical changes for individualized patient management. (https:\/\/jmg.bmj.com\/content\/early\/2019\/07\/12\/jmedgenet-2019-106189<\/a> )<\/p>\n","protected":false},"excerpt":{"rendered":"

Pathogenic variants in a number of genes, conferring high or moderate risks have been associated to hereditary breast cancer. Studying a highly selected cohort of 1,382 Greek breast cancer patients, 436 inherited pathogenic variants distributed in twenty-eight genes, have been identified. Beyond established associations, i.e. high breast cancer risk conferred by TP53 and PALB2 pathogenic […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1303","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nOne in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Pathogenic variants in a number of genes, conferring high or moderate risks have been associated to hereditary breast cancer. Studying a highly selected cohort of 1,382 Greek breast cancer patients, 436 inherited pathogenic variants distributed in twenty-eight genes, have been identified. Beyond established associations, i.e. high breast cancer risk conferred by TP53 and PALB2 pathogenic [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-17T22:15:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T00:36:45+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster)\",\"datePublished\":\"2019-07-17T22:15:59+00:00\",\"dateModified\":\"2026-02-24T00:36:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/\"},\"wordCount\":127,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/\",\"name\":\"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2019-07-17T22:15:59+00:00\",\"dateModified\":\"2026-02-24T00:36:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2019\\\/07\\\/17\\\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/","og_locale":"en_US","og_type":"article","og_title":"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster) - JMG Contact blog","og_description":"Pathogenic variants in a number of genes, conferring high or moderate risks have been associated to hereditary breast cancer. Studying a highly selected cohort of 1,382 Greek breast cancer patients, 436 inherited pathogenic variants distributed in twenty-eight genes, have been identified. Beyond established associations, i.e. high breast cancer risk conferred by TP53 and PALB2 pathogenic [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/","og_site_name":"JMG Contact blog","article_published_time":"2019-07-17T22:15:59+00:00","article_modified_time":"2026-02-24T00:36:45+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster)","datePublished":"2019-07-17T22:15:59+00:00","dateModified":"2026-02-24T00:36:45+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/"},"wordCount":127,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/","url":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/","name":"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2019-07-17T22:15:59+00:00","dateModified":"2026-02-24T00:36:45+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2019\/07\/17\/one-in-three-highly-selected-greek-breast-cancer-patients-carries-a-loss-of-function-variant-in-a-cancer-susceptibility-gene\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"One in three highly selected Greek breast cancer patients carries a loss-of-function variant in a cancer susceptibility gene (Contributed by Dr. Florentia Foster)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1303"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1303\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}